Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2425MR)

This product GTTS-WQ2425MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2425MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7823MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ14526MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ13084MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ416MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ1360MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ13218MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ4650MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ10764MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW